Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

Table 3

Ranking probabilities of different first-line treatment strategies.

Strategy	SUCRA% for OS	SUCRA% for PFS	SUCRA% for ORR	SUCRA% for DCR
ATE	93.4	95.0	13.9	26.9
DUR	71.1	43.4	98.3	74.8
IPI	27.2	53.6	47.0	34.1
PLA	8.4	8.1	40.8	64.2

SUCRA = surface under the cumulative ranking; OS = overall survival; PFS = progression-free survival; ORR = objective response rate; DCR = disease control rate; ATE = atezolizumab; DUR = durvalumab; IPI = ipilimumab; PLA = placebo. All these treatments were combined with chemotherapy.